Justice Targets ‘Serious’ GMP Issues, Hears More from Whistleblowers
This article was originally published in The Gold Sheet
The Justice Department is imposing harsh penalties on manufacturers that commit serious GMP violations and this trend will continue in the foreseeable future. DOJ is also getting more calls from FDA and whistleblowers alleging GMP violations under the False Claims Act.
You may also be interested in...
Pharmaceutical manufacturers need to have whistleblower hotlines in place where employees can anonymously report data integrity problems without fear of reprisal.
Pharmaceutical manufacturers need to have whistleblower hotlines in place where employees can anonymously report data integrity problems. That way there is no fear of reprisal.
Although pharmaceutical company settlements in the millions of dollars now seem customary, a guilty plea to seven felonies could signal aggressive government pursuit of manufacturing and data integrity concerns.